For decades, the options for treating obesity were limited and modest. Diet and exercise advice that worked for some and failed for many. A few older medications with significant side effects and small effects. Bariatric surgery for severe cases. The newer GLP-1 medications have shifted that picture substantially, and Wegovy is the SAHPRA approved semaglutide option specifically for weight management.
This page covers what Wegovy is approved for, who it suits, and what the clinical trial evidence shows.
The SAHPRA Approved Use
Wegovy is approved by SAHPRA as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with:
- A BMI of 30 kg/m² or higher (obesity), or
- A BMI of 27 to 29.9 kg/m² with at least one weight related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease
Adolescents aged 12 and older with obesity are also included in the approved indication.
'Chronic' matters. Obesity is officially recognised as a chronic medical condition. Wegovy is treatment for that condition, not a tool for general weight loss in healthy weight people.
What The Trials Showed
The major weight management trial is STEP-1. It enrolled nearly 2000 adults with obesity (without diabetes), followed them for 68 weeks, and compared Wegovy 2.4 mg to placebo. Both groups received structured lifestyle support.
| Group | Mean weight reduction at 68 weeks |
|---|---|
| Placebo + lifestyle | ~2.4% |
| Wegovy 2.4 mg + lifestyle | ~14.9% |
The STEP-2 trial in people with type 2 diabetes showed slightly smaller reductions (around 10 percent), which is typical for any weight management treatment in people with diabetes. STEP-3 added intensive behavioural therapy, with similar weight outcomes to STEP-1.
About one third of people achieved 20 percent or more weight loss on Wegovy 2.4 mg. Most achieved at least 5 percent. A small minority did not respond meaningfully.
The Trials Also Tracked Other Health Markers
Weight is the headline number but not the only thing that improved in the STEP trials. Reductions were also seen in:
- Waist circumference
- Blood pressure
- HbA1c (in those with elevated baseline)
- Cholesterol and triglycerides
- Markers of inflammation
- Sleep apnoea severity
- Liver fat (in NAFLD studies)
The benefit is broader than the scale. Many of the conditions that come with excess weight improve alongside it.
Who Wegovy Suits Well
- Adults meeting the BMI criteria above
- People who have tried lifestyle changes without sustained success
- People with weight related comorbidities where reduction would meaningfully improve health
- People with cardiovascular disease and excess weight (where the SELECT trial added a specific cardiovascular indication)
- Adolescents aged 12 and older with obesity (under appropriate specialist guidance)
- People who understand it is a long term treatment
- People without contraindications
Who Wegovy Does Not Suit
- People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- People with severe gastrointestinal disease, particularly gastroparesis
- People with a history of pancreatitis or active pancreatic disease
- People with active gallbladder disease (relative contraindication)
- Pregnant women or those actively trying to conceive (stop at least two months before)
- People with type 1 diabetes (different mechanism, not indicated)
- People with severe kidney disease (caution, monitoring needed)
- People with a history of severe eating disorders (case by case, but requires careful assessment)
- People with a history of suicidal ideation (postmarketing reports require careful assessment)
Find Out If You Qualify
An online consultation reviews your medical history against the eligibility criteria and works out whether Wegovy is appropriate.
Start ConsultationRealistic Expectations
The first month (0.25 mg)
The starting dose is below therapeutic level. Appetite changes are usually noticeable. Weight changes are usually modest. Side effects (mostly nausea) are common but tend to settle.
Months two to four (titration)
Dose increases progressively to 2.4 mg over the 0.5, 1.0, 1.7 mg steps. The effect strengthens. Weight reduction often progresses steadily, though not linearly. Side effects may briefly flare with each dose increase, then settle.
Months five to twelve (maintenance dose)
Most of the trial weight reduction happens over the first 12 months at full dose. Many people reach a stable pattern.
Beyond twelve months
Treatment is continued long term. Stopping leads to weight regain, as the underlying appetite signalling returns to baseline. Long term continuation is discussed with the treating doctor over time.
Why Diet And Exercise Still Matter
Three reasons.
Mechanism. The medication reduces appetite. If you eat past the appetite reduction, the effect is muted. People who do not adjust their eating get smaller results.
Muscle preservation. Significant weight loss without resistance training causes lean mass loss. Adequate protein intake and resistance exercise during treatment reduce this.
Long term health. Wegovy improves several health markers, but eating quality and exercise still independently contribute. The combination is stronger than the medication alone.
What This Page Is Not
This page does not give calorie targets, weight goals, or 'how much you should aim to lose'. Those are individual decisions made between a person and their treating doctor based on starting weight, health status, and what is realistic and safe. Wegovy is medical treatment for a medical condition. The goal is health improvement.
Related Reading
Frequently Asked
The STEP-1 trial in adults with obesity showed mean weight reduction of around 15 percent at 68 weeks at the full 2.4 mg dose, compared to around 2.4 percent on placebo. Individual results vary considerably.
Only while continuing treatment. Studies (including STEP-4 specifically) show that stopping leads to gradual weight regain over the following year. Wegovy is intended as a long term treatment for a chronic condition.
Some lean mass loss is expected with any significant weight loss. Resistance training and adequate protein intake during treatment reduce this. Discuss with your treating doctor.
The SAHPRA indication specifically pairs Wegovy with a reduced calorie diet and increased physical activity. The medication makes eating less easier by reducing appetite, but the underlying calorie reduction is what produces weight loss.